DNTH

insider transactions

Dianthus Therapeutics, Inc. /DE/ — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 30d

-56.5K

0 buy · 56.5K sell

Net value · 30d

-$4.8M

$0 in · $4.8M out

Sentiment · 30d

Net selling

0% buying · 100% selling

Open-market trades · 30d

0 buy · 56.5K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Exercise·M
Jun 17, 26

Veness Adam M

SVP, General Counsel and Sec. · 10b5-1

$0

30.0K sh

Own +60%
Sell·S
Jun 17, 26

Veness Adam M

SVP, General Counsel and Sec. · 10b5-1

$1.1M

13.2K sh · $81.38

Own -100%
Sell·S
Jun 17, 26

Veness Adam M

SVP, General Counsel and Sec. · 10b5-1

$1.3M

16.8K sh · $80.34

Own -56%
Exercise·M
Jun 17, 26

Veness Adam M

SVP, General Counsel and Sec. · 10b5-1

$536.4K

30.0K sh · $17.88

Own New
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$0

9.4K sh

Own +11%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$0

6.2K sh

Own +15%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$0

6.9K sh

Own +12%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$0

4.0K sh

Own New
Sell·S
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$380.0K

4.2K sh · $91.37

Own -51%
Sell·S
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$1.5M

16.9K sh · $90.72

Own -67%
Sell·S
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$487.0K

5.4K sh · $89.72

Own -18%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$206.9K

9.4K sh · $22.07

Own +44%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$136.0K

6.2K sh · $21.77

Own +42%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$123.5K

6.9K sh · $17.88

Own +86%
Exercise·M
Jun 1, 26

Randhawa Simrat

EVP, Head of R&D · 10b5-1

$33.7K

4.0K sh · $8.44

Own +100%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 17, 2026	Veness Adam M 10b5-1	SVP, General Counsel and Sec.	Exercise M	30.0K	+60%	—	$0
Jun 17, 2026	Veness Adam M 10b5-1	SVP, General Counsel and Sec.	Sell S	13.2K	-100%	$81.38	$1.1M
Jun 17, 2026	Veness Adam M 10b5-1	SVP, General Counsel and Sec.	Sell S	16.8K	-56%	$80.34	$1.3M
Jun 17, 2026	Veness Adam M 10b5-1	SVP, General Counsel and Sec.	Exercise M	30.0K	New	$17.88	$536.4K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	9.4K	+11%	—	$0
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	6.2K	+15%	—	$0
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	6.9K	+12%	—	$0
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	4.0K	New	—	$0
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Sell S	4.2K	-51%	$91.37	$380.0K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Sell S	16.9K	-67%	$90.72	$1.5M
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Sell S	5.4K	-18%	$89.72	$487.0K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	9.4K	+44%	$22.07	$206.9K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	6.2K	+42%	$21.77	$136.0K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	6.9K	+86%	$17.88	$123.5K
Jun 1, 2026	Randhawa Simrat 10b5-1	EVP, Head of R&D	Exercise M	4.0K	+100%	$8.44	$33.7K

About DNTH insider trading

This page tracks insider transactions for Dianthus Therapeutics, Inc. /DE/ (DNTH) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.